[go: up one dir, main page]

NO20063267L - The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist - Google Patents

The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist

Info

Publication number
NO20063267L
NO20063267L NO20063267A NO20063267A NO20063267L NO 20063267 L NO20063267 L NO 20063267L NO 20063267 A NO20063267 A NO 20063267A NO 20063267 A NO20063267 A NO 20063267A NO 20063267 L NO20063267 L NO 20063267L
Authority
NO
Norway
Prior art keywords
disorder
disorders
serotonin reuptake
reuptake inhibitor
agonist
Prior art date
Application number
NO20063267A
Other languages
Norwegian (no)
Inventor
Thomas Ivo Franciscus Cremers
Sandra Hogg Willigers
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of NO20063267L publication Critical patent/NO20063267L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Oppfinnelsen vedrører anvendelsen av en forbindelse, som er en serotoninreopptaksinhibitor, og en annen forbindelse, som er en H3-reseptorantagonist, invers agonist eller partiell agonist for fremstillingen av en farmasøytisk sammensetning for behandlingen av depresjon, angstlidelser og andre affektive lidelser, slik som generalisert angstlidelse, panikkangst, obsessiv-kompulsiv lidelse, akutt stresslidelse, posttraumatisk stresslidelse og sosial angstlidelse, spiseforstyrrelser slik som bulimi, anoreksi og obesitet, fobier, dystymi, premenstruelt syndrom, kognitive lidelser, impulskontrollidelser, oppmerksomhetssvikt-hyperaktivitets-syndromet, medikamentmisbruk eller enhver annen lidelse som reagerer på serotonin-reopptaksinhibitor.The invention relates to the use of a compound which is a serotonin reuptake inhibitor and another compound which is an H3 receptor antagonist, inverse agonist or partial agonist for the preparation of a pharmaceutical composition for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder. panic anxiety, obsessive-compulsive disorder, acute stress disorder, post-traumatic stress disorder and social anxiety disorder, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention-deficit disorder, attention deficit disorder responds to serotonin reuptake inhibitor.

NO20063267A 2003-12-15 2006-07-13 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist NO20063267L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52949103P 2003-12-15 2003-12-15
DKPA200301854 2003-12-15
PCT/DK2004/000862 WO2005056056A2 (en) 2003-12-15 2004-12-14 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist

Publications (1)

Publication Number Publication Date
NO20063267L true NO20063267L (en) 2006-07-13

Family

ID=34680191

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20063267A NO20063267L (en) 2003-12-15 2006-07-13 The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist

Country Status (6)

Country Link
EP (1) EP1696896A2 (en)
JP (1) JP2007513896A (en)
AU (1) AU2004296531A1 (en)
BR (1) BRPI0415899A (en)
NO (1) NO20063267L (en)
WO (1) WO2005056056A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003150A (en) 2003-09-17 2006-08-31 Johnson & Johnson Fused heterocyclic compounds.
US7598255B2 (en) 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
US7728031B2 (en) 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
EP2188288A1 (en) 2007-09-11 2010-05-26 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole n-oxides
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP4268802A4 (en) * 2020-12-23 2024-11-06 Shanghai Yonsun Biotechnology Co., Ltd. PHARMACEUTICAL VILAZODONE COMPOSITION, MANUFACTURING PROCESS THEREOF AND USE THEREOF
AU2024230525A1 (en) * 2023-02-28 2025-10-09 Biohaven Therapeutics Ltd. Methods for treating obsessive compulsive related disorders, tic disorders and glutamate excitotoxicity related disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999020279A1 (en) * 1997-10-17 1999-04-29 Eli Lilly And Company Potentiation of pharmaceuticals
EP0958824A3 (en) * 1998-05-22 1999-12-01 Eli Lilly And Company Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression
SK17492000A3 (en) * 1998-05-29 2002-04-04 Eli Lilly And Company Combination therapy for treatment of bipolar disorders
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications

Also Published As

Publication number Publication date
WO2005056056A2 (en) 2005-06-23
AU2004296531A1 (en) 2005-06-23
WO2005056056A3 (en) 2006-02-02
JP2007513896A (en) 2007-05-31
BRPI0415899A (en) 2007-01-09
EP1696896A2 (en) 2006-09-06

Similar Documents

Publication Publication Date Title
NO20045552L (en) Combination therapy using a serotonin reuptake inhibitor
CY1114660T1 (en) 2-DIAMONDERY PRODUCTION AS ECLECTIVE INGREDIENTS 11b-HSD1
NO20071343L (en) Substituted phenylaminothiazoles and their use
DE602005018758D1 (en) AM HISTAMINE H3 RECEPTOR EFFECTIVE AGENT, MANUFACTURE AND THERAPEUTIC APPLICATIONS
ATE538650T1 (en) CANNABINOID RECEPTOR ANTAGONISTS / INVERSE AGONISTS FOR THE TREATMENT OF OBESITY
NO20083204L (en) Combination of an H3 antagonist / inverse agonist and an appetite suppressant
EA200600049A1 (en) METHODS OF OBTAINING 3 - BENZEPEPINES
NO20064156L (en) Indazole carboxamide compounds as 5-HT 4 receptor agonists
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
NO20051769L (en) Antidepressant Azaheterocycyl Methyl Derivatives of Heterocycle Condensed Benzodioxanes
NO20076638L (en) New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor
NO20063267L (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
NO20083065L (en) New N-sulfamoylpiperidinamides for prophylaxis or treatment of obesity and related conditions
EA200601158A1 (en) COMBINATION OF SEROTONIN RETURN CAPTURE INHIBITOR AND ANTAGONIST, REVERSE AGONIST OR PARTIAL AGONIST OF HISTAMINE 3 RECEPTOR
ATE281459T1 (en) AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO(2,3-F)QUINOLINE AS ANTIDEPRESSANTS
NO20061167L (en) The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
NO20035673L (en) New heteroaryl derivatives, their preparation and use
RU2019132041A (en) 2,6-DISPLACED PYRIDINE DERIVATIVE
ATE370953T1 (en) ANTIDEPRESSIVE INDOLALKYL DERIVATIVES OF HETEROCYCLIC CONDENSED BENZODIOXANE METHYLAMINES
NO20051617L (en) Piperidine derivatives of heterocycle-fused benzodioxanes with antidepressant activity
NO20055205L (en) 4- (2-Phenylsulfanyl-phenyl) -1,2,3,6-tithropyridine derivatives as serotonin uptake inhibitors
PT1546151E (en) DERIVATIVES OF HETEROCYCLICS FUNDED WITH BENZODIOXANOS CYCLOALQUILAMINE ANTI-DEPRESSIVES
BRPI0412268A (en) compounds containing a selective serotonin reuptake inhibitor and 5-ht2a receptor antagonist
JP2007513896A5 (en)
AR039723A1 (en) COMBINATION THERAPY WHERE A SEROTONINE RECOVERY INHIBITOR IS USED

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN & VINGTOFT, POSTBOKS 1003 SENTRUM, 0104